Casadevall N, Belanger C, Goy A, Varet B, Lang J, Poisson D
Laboratoire d'hématologie, Groupe Hospitalier Cochin, Paris.
Acta Haematol. 1992;87 Suppl 1:25-7. doi: 10.1159/000204785.
As the importance of recombinant human erythropoietin (r-HuEPO) therapy has been clearly demonstrated in anaemic patients with chronic renal failure (CRF), we carried out an open, non-randomized, non-placebo-controlled trial of high-dose intravenous (i.v.) r-HuEPO (100,000 U twice weekly) therapy in 14 anaemic, transfusion-dependent patients. Clinical response was defined by a rise in haemoglobin concentration to 9-11 g/dl and/or a reduction in the transfusion requirement during the treatment period compared with the 12 weeks before treatment. Eight patients completed the 12-week treatment and 4 were still under treatment, 1 at 10 weeks, 2 at 8 weeks and 1 at 4 weeks. Only those patients completing treatment were included in the efficacy evaluation. After treatment there was no significant change in haemoglobin concentrations, reticulocyte counts, or transfusion requirements. However, the number of patients included is too low to allow any definitive conclusion to be made.
由于重组人促红细胞生成素（r-HuEPO）疗法在慢性肾功能衰竭（CRF）贫血患者中的重要性已得到明确证实，我们对14例贫血且依赖输血的患者进行了一项开放性、非随机、非安慰剂对照试验，采用高剂量静脉注射（i.v.）r-HuEPO（每周两次，每次100,000 U）治疗。临床反应的定义为治疗期间血红蛋白浓度升至9 - 11 g/dl和/或与治疗前12周相比输血需求减少。8例患者完成了12周的治疗，4例仍在治疗中，1例治疗10周，2例治疗8周，1例治疗4周。仅将完成治疗的患者纳入疗效评估。治疗后，血红蛋白浓度、网织红细胞计数或输血需求均无显著变化。然而，纳入的患者数量过少，无法得出任何确定性结论。
